Sovesudil is found to be Safe & Effective for the treatment
A Study was conducted to evaluate ocular hypotensive efficacy and the safety of sovesudil, a novel Rho-associated protein kinase (ROCK) inhibitor, in patients with normal-tension glaucoma (NTG).

Patients with NTG (unmedicated baseline IOP less than 21 mmHg) were randomized in 3 groups and treated with sovesudil in concentrations of 0.25% and 0.5%, or with a placebo three times daily (TID) for 4 weeks. The primary end-point was the mean diurnal IOP change from the baseline at week 4. Safety was recorded over a 4-week treatment period and the following 2-week observation period.

--A total of 119 patients were included in the primary efficacy analysis.

--The mean diurnal IOP change from the baseline at week 4 was -1.56 mmHg for the high-dose group, -1.10 mmHg for the low-dose group and -0.65 mmHg for the placebo group.

--The difference between the high-dose and the placebo groups was -0.91 mmHg. 0.5% sovesudil TID met the criteria for superiority to the placebo.

--The most frequent ocular adverse event among sovesudil-treated patients was conjunctival hyperaemia (24.4% for the high-dose and 17.5% for the low-dose group) and predominately classified as mild.

Finally, at week 4, Sovesudil 0.25 % and 0.5 % TID demonstrated statistically significant IOP-lowering effects, and the IOP-lowering benefits of the 0.5 percent concentration fulfilled the superiority requirements in comparison to the placebo. Sovesudil was well tolerated, with only minor side effects, such as a modest frequency of conjunctival hyperaemia in NTG patients.